| CAS NO: | 882366-16-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 询价 |
| 10mg | 询价 |
| 25mg | 询价 |
| 50mg | 询价 |
| 100mg | 询价 |
| 250mg | 询价 |
| 500mg | 询价 |
| Name: SBI-115 CAS#: 882366-16-7 Chemical Formula: C14H13ClN2O4S Exact Mass: 340.0285 Molecular Weight: 340.778 | |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Technical Information | Synonym: SBI115; SBI 115; SBI-115 Chemical Name: 4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester InChi Key: IJPXOPBVXVPPEW-UHFFFAOYSA-N InChi Code: InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3 SMILES Code: O=C(C1=NC(S(=O)(CC)=O)=NC=C1Cl)OC2=CC=CC(C)=C2 |
| In Vitro | SBI-115 (100 and 200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes[1]. Cell Proliferation Assay[1] Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100 and 200 μM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. |
|---|---|
| Reference | Hepatology. 2017 Oct; 66(4):1197-1218. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |
